Targeting BRAF for patients with melanoma

por Arkenau, H-T, Kefford, R, Long, G V
Publicado 2011

Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience

por Arkenau, H-T, Olmos, D, Ang, J E, de Bono, J, Judson, I, Kaye, S
Publicado 2008

Reply: Clinical outcome and prognostic factors for patients treated within a phase I study: the Royal Marsden Hospital Experience

por Olmos, D, Arkenau, H-T, Ang, J E, de Bono, J S, Judson, I, Kaye, S B
Publicado 2008

Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase II trial

por Nehls, O, Klump, B, Arkenau, H T, Hass, H G, Greschniok, A, Gregor, M, Porschen, R
Publicado 2002

Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter?

por Postel-Vinay, S, Arkenau, H-T, Olmos, D, Ang, J, Barriuso, J, Ashley, S, Banerji, U, De-Bono, J, Judson, I, Kaye, S
Publicado 2009

Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1–4 inhibitor in patients with advanced solid tumors

por Bahleda, R., Meric-Bernstam, F., Goyal, L., Tran, B., He, Y., Yamamiya, I., Benhadji, K. A., Matos, I., Arkenau, H.-T.
Publicado 2020

Studies on p53, BAX and Bcl-2 protein expression and microsatellite instability in stage III (UICC) colon cancer treated by adjuvant chemotherapy: major prognostic impact of proapo...

por Nehls, O, Okech, T, Hsieh, C-J, Enzinger, T, Sarbia, M, Borchard, F, Gruenagel, H-H, Gaco, V, Hass, H G, Arkenau, H T, Hartmann, J T, Porschen, R, Gregor, M, Klump, B
Publicado 2007

PB2099: A FIRST-IN-HUMAN PHASE 1 TRIAL OF NX-1607, A FIRST-IN-CLASS ORAL CBL-B INHIBITOR, IN PATIENTS WITH ADVANCED MALIGNANCIES INCLUDING RICHTER TRANSFORMATION DLBCL

por Sharp, A., Williams, A., Blagden, S., Plummer, R., Hochhauser, D., Krebs, M. G., Pacey, S., Evans, J., Whelan, S., Nandakumar, S., Rogers, S., Jameson, K. L., Basile, F. G., de Bono, J., Arkenau, H.-T.
Publicado 2022

Pooled safety analysis from phase III studies of trifluridine/tipiracil in patients with metastatic gastric or gastroesophageal junction cancer and metastatic colorectal cancer

por Van Cutsem, E., Hochster, H., Shitara, K., Mayer, R., Ohtsu, A., Falcone, A., Yoshino, T., Doi, T., Ilson, D.H., Arkenau, H.-T., George, B., Benhadji, K.A., Makris, L., Tabernero, J.
Publicado 2022

Trifluridine/tipiracil versus placebo for third or later lines of treatment in metastatic gastric cancer: an exploratory subgroup analysis from the TAGS study

por Tabernero, J., Shitara, K., Zaanan, A., Doi, T., Lorenzen, S., Van Cutsem, E., Fornaro, L., Catenacci, D.V.T., Fougeray, R., Moreno, S.R., Azcue, P., Arkenau, H.-T., Alsina, M., Ilson, D.H.
Publicado 2021

Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes fro...

por Kopetz, S., Grothey, A., Van Cutsem, E., Yaeger, R., Wasan, H., Yoshino, T., Desai, J., Ciardiello, F., Loupakis, F., Hong, Y.S., Steeghs, N., Guren, T.K., Arkenau, H.-T., Garcia-Alfonso, P., Belani, A., Zhang, X., Tabernero, J.
Publicado 2022

Prediction of early death among patients enrolled in phase I trials: development and validation of a new model based on platelet count and albumin

por Ploquin, A, Olmos, D, Lacombe, D, A'Hern, R, Duhamel, A, Twelves, C, Marsoni, S, Morales-Barrera, R, Soria, J-C, Verweij, J, Voest, E E, Schöffski, P, Schellens, J H, Kramar, A, Kristeleit, R S, Arkenau, H-T, Kaye, S B, Penel, N
Publicado 2012

The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escal...

por Molife, L R, Fong, P C, Paccagnella, L, Reid, A H M, Shaw, H M, Vidal, L, Arkenau, H-T, Karavasilis, V, Yap, T A, Olmos, D, Spicer, J, Postel-Vinay, S, Yin, D, Lipton, A, Demers, L, Leitzel, K, Gualberto, A, de Bono, J S
Publicado 2010